Twitter | Search | |
Search Refresh
AmpBioResearch Jun 14
Same mechanism as ARQL 531 and cohort now in ascending Ph1b that should start to show efficacy. Last data presentation for was . Not saying data will look cleanly efficacious like ARQL 531. Ph1b trials way too unpredictable for that and each Btk has unique profile.
Reply Retweet Like
Michael Makris Dec 8
During ASH 2018 there were 37,000 tweets, 6680 twitters and 330 tweets/hr. Overall 160 million impressions. May be in future we need subject specific () rather than meeting specific () hashtags. ASH is dominated by malignant .
Reply Retweet Like
Mazie Tsang Dec 10
Tips for Success in clinical research: 1. Worth your time? 2. Multiple mentors 3. Get to work 4. Choose projects wisely 5. Clinical practice guides ?s 6. Create databases 7. Invest in yourself 8. Get funding 10. Choose collaborators well 11. Rejection not fatal
Reply Retweet Like
Rob Dean, MD Dec 4
Just when you think that flying ✈️ can’t get more silly, makes every attendee from remove the two-pound Education Book 📖 from their checked bag 🧳 and carry it on, because their security scanners can’t handle the density (of the knowledge! 🧠).
Reply Retweet Like
Jacob Plieth Dec 4
Post chillaxing time
Reply Retweet Like
Mohamad Mohty Dec 9
Amazing era for hematology
Reply Retweet Like
Sagar Lonial MD Dec 4
Interesting ride? By bye San Diego ⁦⁩ ⁦
Reply Retweet Like
Russell Ryan Dec 10
I’m excited and honored to receive a 2019 Junior Faculty Scholar Award from the American Society of Hematology. Feeling inspired by all the great research I saw a week ago at .
Reply Retweet Like
Tim Fenske Dec 22
I’m a little late but wanted to congratulate one of our ⁦⁩ residents Ensi Voshtina on presenting at
Reply Retweet Like
Mehdi Hamadani Feb 5
Sharing space with favorites editor & hematologist in
Reply Retweet Like
Michael Makris Dec 9
It was great to see the results of the PAUSE trial that was presented at about surgery in patients on undergoing surgery or procedures. Temporary discontinuation is safe and effective with no bridging needed. Confirms our clinical practice.
Reply Retweet Like
Husam Qanash Dec 5
It was a very great opportunity and experience to present my Ph.D. project at . Thank you to &
Reply Retweet Like
CML AdvocatesNetwork Dec 17
Reply Retweet Like
Ola Landgren, M.D. Dec 8
KRd combination therapy has deeper treatment responses (compared to VRd) leading to better event-free survival in newly diagnosed multiple myeloma: a nested case-control study based on the CoMMpass study ⁩ ⁦
Reply Retweet Like
Alexis Thompson Jan 16
Numerous advances in curative therapies for were presented at . Very important times to engage patients and their families for in depth discussions of treatment options.
Reply Retweet Like
Hetty Carraway Dec 4
Dr Mikkael Sekeres & Dr Mark Crowther moderated an amazing line up of for fantastic late breaking abstract session at ! Drs. Khorana, Falcon, Serrano, Shanafelt, Douketis & Blombery. ⁦⁩ ⁦⁩ ⁦⁩ ⁦
Reply Retweet Like
Lucas Cantadori Dec 6
I would like to thank all the colleagues that tweeted on . It was a great help for those who couldn’t attend this year!
Reply Retweet Like
Cleveland Clinic MD Dec 4
. discusses the results of a new study that showed oral anticoagulants are effective at preventing blood clots in high-risk cancer patients.
Reply Retweet Like
Jack Khouri Jan 4
Our awesome ⁩ presenting her oral abstract on discrepancies. Great data!!
Reply Retweet Like
Hetty Carraway Dec 4
Dr Alok Khorana led off the late breaking abstract session this morning with excellent presentation on Cassini study showing decreased VTE events and VTE deaths in solid tumor patients when txtd with rivaroxaban.
Reply Retweet Like